AI to predict breast cancer treatment response
Part of Cancer, Skin clinical trials.
This trial uses artificial intelligence to analyze tissue samples and predict how well a targeted therapy called Pyrotinib works for advanced breast cancer. It aims to help doctors choose the best treatment for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You must have advanced breast cancer that has spread to other parts of the body (stage IV).
- Your cancer's HER2 status must be known.
- You must have received at least two cycles of Pyrotinib alone (not with other drugs).
- You must have stored tissue samples (slides) from before treatment that are good quality.
- You need to have regular follow-up data on how your cancer responded to treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an artificial intelligence model can help doctors choose the best targeted therapy before surgery for HER2-positive breast cancer (a type of breast cancer with a protein called HER2). The goal is to improve how well the treatment works and reduce side effects.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
This study tests whether an AI tool can predict how well breast cancer responds to chemotherapy given before surgery. Your tumor sample from a needle biopsy will be analyzed to see if the AI's prediction matches your actual treatment outcome.
This trial uses an artificial intelligence model to predict how well breast cancer responds to neoadjuvant therapy (treatment before surgery). It aims to improve treatment planning by analyzing MRI scans taken before and after therapy.
This trial uses artificial intelligence to analyze images of your tumor tissue to predict if breast cancer might spread to other parts of the body. It may help doctors better understand your individual risk and guide treatment decisions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.